Founder and President, Innovative Genomics Institute
Dr. Jennifer A. Doudna is the Li Ka Shing Chancellor’s Chair and a Professor in the Departments of Chemistry and of Molecular and Cell Biology at the University of California, Berkeley. Her groundbreaking development of CRISPR-Cas9 as a genome-engineering technology, with collaborator Emmanuelle Charpentier, earned the two the 2020 Nobel Prize in Chemistry and forever changed the course of human and agricultural genomics research.
This powerful technology enables scientists to change DNA — the code of life — with a precision only dreamed of just a few years ago. Labs worldwide have re-directed the course of their research programs to incorporate this new tool, creating a CRISPR revolution with huge implications across biology and medicine.
In addition to her scientific achievements, Doudna is a leader in public discussion of the ethical implications of genome editing for human biology and societies, and advocates for thoughtful approaches to the development of policies around the safe use of CRISPR technology.
Doudna is an investigator with the Howard Hughes Medical Institute, senior investigator at Gladstone Institutes, and the President of the Innovative Genomics Institute. She co-founded and serves on the advisory panel of several companies that use CRISPR technology in unique ways.
She is a member of the National Academy of Sciences, the National Academy of Medicine, the National Academy of Inventors, and the American Academy of Arts and Sciences. Doudna is also a Foreign Member of the Royal Society and has received numerous other honors including the Breakthrough Prize in Life Sciences (2015), the Japan Prize (2016), Kavli Prize (2018), the LUI Che Woo Welfare Betterment Prize (2019), and the Wolf Prize in Medicine (2020). Doudna’s work led TIME to recognize her as one of the “100 Most Influential People” in 2015 and a runner-up for “Person of the Year” in 2016. She is the co-author of “A Crack in Creation,” a personal account of her research and the societal and ethical implications of gene editing.
Recent work from Jennifer and her lab has focused on development of new tools for genome editing, cutting-edge research into delivery techniques for CRISPR-based therapies, next-generation CRISPR diagnostics, and continued investigations into the structure and mechanism of CRISPR-Cas systems.
In 2020, the COVID-19 pandemic prompted Jennifer and members of the Doudna Lab to quickly establish a pop-up diagnostic testing lab at the IGI, and pivot to rapid research projects to help address the crisis.
Selected recent publications below. For a full list of Doudna Lab publications, click here.
Collins FS, Doudna JA, Lander ES, and Rotimi CN. The New England Journal of Medicine(2021)
Pausch P, Al-Shayeb B, Bisom-Rapp E, Tsuchida CA, Li Z, Cress BF, Knott GJ, Jacobsen SE, Banfield JF, and Doudna JA. Science(2020)
Amen AM, Barry KW, Boyle JM, Brook CE, Choo S, Cornmesser LT, Dilworth DJ, Doudna JA, Ehrenberg AJ, Fedrigo I, Friedline SE, Graham TGW, Green R, Hamilton JR, Hirsh A, Hochstrasser ML, Hockemeyer D, Krishnappa N, Lari A, Li H, Lin-Shiao E, Lu T, Lyons EF, Mark KG, Martell LA, Martins ARO, McDevitt SL, Mitchell PS, Moehle EA, Naca C, Nandakumar D, O'Brien E, Pappas DJ, Pestal K, Quach DL, Rubin BE, Sachdeva R, Stahl EC, Syed AM, Tan I, Tsuchida CA, Tollner A, Tsui CK, Turkalo TK, Urnov FD, Warf MB, Whitney ON, and Witkowsky LB. Nature Biotechnology(2020)
Al-Shayeb B, Sachdeva R, Chen LX, Ward F, Munk P, Devoto A, Castelle CJ, Olm MR, Bouma-Gregson K, Amano Y, He C, Méheust R, Brooks B, Thomas A, Lavy A, Matheus-Carnevali P, Sun C, Goltsman DSA, Borton MA, Sharrar A, Jaffe AL, Nelson TC, Kantor R, Keren R, Lane KR, Farag IF, Lei S, Finstad K, Amundson R, Anantharaman K, Zhou J, Probst AJ, Power ME, Tringe SG, Li WJ, Wrighton K, Harrison S, Morowitz M, Relman DA, Doudna JA, Lehours AC, Warren L, Cate JHD, Santini JM, and Banfield JF. Nature(2020)
Doudna JA. Nature(2020)
Learn more about CRISPR genome editing and the story of its journey from curiosity-driven basic research to a groundbreaking tool:
On October 7, 2020, Jennifer Doudna and Emmanuelle Charpentier were awarded the Nobel Prize in Chemistry for their work on developing CRISPR-Cas9 as a genome-editing tool. Learn more about the announcement, and the history of the research that led up to the prize:
Watch Jennifer's Nobel Prize lecture from December 8, 2020 on the history of her work on CRISPR-Cas9 and future directions for genome editing research:
A popular science book about her personal and professional experiences in CRISPR research from IGI founder Jennifer Doudna and her former graduate student, Sam Sternberg, A Crack in Creation offers a behind-the-scenes look at the development of CRISPR genome editing technology, its applications, and ethical implications.
Described as “required reading for every concerned citizen” by the New York Review of Books, A Crack in Creation (2017) takes the reader on a scientific journey, vividly exploring an unexpected discovery that has reshaped the future of humanity in just a short time.
Human Nature, a feature from executive producer Dan Rather and director Adam Bolt, breaks down the science behind CRISPR and encourages viewers to think about the potential implications of this transformative innovation. Includes interviews with Jennifer Doudna, as well as IGI scientific directors Jill Banfield and Fyodor Urnov.
Photos of Jennifer Doudna for media and educational use are available to download here. Photos must be accompanied by an attribution as specified in the download. If there is no specification, please attribute the photo to "Innovative Genomics Institute, UC Berkeley."